RYTM
Rhythm Pharmaceuticals, Inc.
Price Chart
Latest Quote
$96.79
+0.96 (+1.00%)
Current Price
| Previous Close | $95.83 |
| Open | $97.56 |
| Day High | $99.95 |
| Day Low | $96.39 |
| Volume | 1,463,992 |
Stock Information
| Shares Outstanding | 68.59M |
| Total Debt | $112.31M |
| Cash Equivalents | $340.62M |
| Revenue | $217.16M |
| Net Income | $-207.84M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $6.64B |
| EPS (TTM) | $-3.13 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $6.52B |
| Sales | $217.16M |
| Income | $-207.84M |
| Book/sh | $1.80 |
| Cash/sh | $4.97 |
| Employees | 414 |
Financial Ratios
| Quick Ratio | 3.63 |
| Current Ratio | 4.17 |
| Debt/Eq | 47.26 |
Returns & Margins
| ROA | -29.76% |
| ROE | -101.16% |
| Gross Margin | 89.41% |
| Operating Margin | -87.11% |
| Profit Margin | -93.33% |
Ownership
| Insider Ownership | 0.77% |
| Institutional Ownership | 109.97% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -130.56 |
| P/S | 30.57 |
| P/B | 53.89 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $139.47 |
Technical Indicators
| SMA20 | $88.95 |
| SMA50 | $88.36 |
| SMA200 | $97.77 |
| RSI | 67.59 |
| ATR | 4.5306 |
| Shares Float | 55.70M |
| Short Float | 11.62% |
| Short Ratio | 10.16 |
| Volatility | 1.92 |
| Rel Volume | 2.11 |
Performance History
| Week | +10.42% |
| Month | +10.98% |
| Quarter | +7.18% |
| 6 Months | -13.93% |
| YTD | -7.83% |
| Year | +56.19% |
| 3 Years | +443.46% |
| 5 Years | +407.29% |
| 10 Years | +293.94% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $96.79 | 1,559,000 |
| 2026-06-17 | $95.83 | 1,741,100 |
| 2026-06-16 | $89.72 | 609,500 |
| 2026-06-15 | $89.70 | 2,259,600 |
| 2026-06-12 | $88.38 | 554,400 |
| 2026-06-11 | $87.66 | 684,100 |
| 2026-06-10 | $85.71 | 852,100 |
| 2026-06-09 | $87.86 | 626,400 |
| 2026-06-08 | $85.93 | 489,300 |
| 2026-06-05 | $86.40 | 446,300 |
| 2026-06-04 | $87.61 | 393,000 |
| 2026-06-03 | $84.71 | 416,100 |
| 2026-06-02 | $84.35 | 536,000 |
| 2026-06-01 | $87.87 | 468,200 |
| 2026-05-29 | $88.32 | 757,900 |
| 2026-05-28 | $92.98 | 549,000 |
| 2026-05-27 | $91.42 | 495,700 |
| 2026-05-26 | $89.82 | 322,700 |
| 2026-05-22 | $87.84 | 479,100 |
| 2026-05-21 | $90.19 | 539,500 |
| 2026-05-20 | $90.64 | 496,700 |
| 2026-05-19 | $87.21 | 527,800 |
About Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and AlstrÃļm syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
đ° Latest News
Rhythm Pharmaceuticals posts long-term setmelanotide data for obesity
Proactive âĸ 2026-06-16T15:37:00Z
The Battle Against Genetic Obesity Just Sent This Biotech Stock Flying
Investor's Business Daily âĸ 2026-06-15T21:10:03Z
How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Updating Its Bardet-Biedl Diagnosis Algorithm
Simply Wall St. âĸ 2026-06-08T02:10:28Z
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Simply Wall St. âĸ 2026-05-08T14:00:15Z
Rhythm Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-06T12:30:00Z
Why Rhythm Pharmaceuticals Stock Triumphed on Tuesday
Motley Fool âĸ 2026-05-06T00:00:09Z
Rhythm Pharmaceuticals Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-05T20:20:10Z
Rhythm Pharmaceuticals Weighs Long Term IMCIVREE Data And Growth Potential
Simply Wall St. âĸ 2026-05-05T19:19:59Z
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Tops Revenue Estimates
Zacks âĸ 2026-05-05T12:25:07Z
How The Rhythm Pharmaceuticals (RYTM) Narrative Is Shifting On EMANATE Results And IMCIVREE Expansion
Simply Wall St. âĸ 2026-05-04T23:13:41Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $19,492,000 | $13,368,000 | $9,302,000 | $2,133,000 |
| Cost Of Revenue | $19,492,000 | $13,368,000 | $9,302,000 | $2,133,000 |
| Total Revenue | $189,757,000 | $130,126,000 | $77,428,000 | $23,638,000 |
| Operating Revenue | $189,757,000 | $130,126,000 | $77,428,000 | $23,638,000 |
| Expenses | ||||
| Interest Expense | $20,583,000 | $20,603,000 | $13,892,000 | $5,201,000 |
| Total Expenses | $381,773,000 | $395,629,000 | $261,785,000 | $202,795,000 |
| Other Income Expense | $1,264,000 | $11,139,000 | $190,000 | $-790,000 |
| Other Non Operating Income Expenses | $1,264,000 | $2,239,000 | $190,000 | $-790,000 |
| Net Non Operating Interest Income Expense | $-5,290,000 | $-5,892,000 | $53,000 | $-1,172,000 |
| Interest Expense Non Operating | $20,583,000 | $20,603,000 | $13,892,000 | $5,201,000 |
| Operating Expense | $362,281,000 | $382,261,000 | $252,483,000 | $200,662,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-196,539,000 | $-260,602,000 | $-184,678,000 | $-181,119,000 |
| Net Interest Income | $-5,290,000 | $-5,892,000 | $53,000 | $-1,172,000 |
| Interest Income | $15,293,000 | $14,711,000 | $13,945,000 | $4,029,000 |
| Normalized Income | $-196,539,000 | $-267,633,000 | $-184,678,000 | $-181,119,000 |
| Net Income From Continuing And Discontinued Operation | $-196,539,000 | $-260,602,000 | $-184,678,000 | $-181,119,000 |
| Total Operating Income As Reported | $-192,016,000 | $-265,503,000 | $-184,357,000 | $-179,157,000 |
| Net Income Common Stockholders | $-201,917,000 | $-264,572,000 | $-184,678,000 | $-181,119,000 |
| Net Income | $-196,539,000 | $-260,602,000 | $-184,678,000 | $-181,119,000 |
| Net Income Including Noncontrolling Interests | $-196,539,000 | $-260,602,000 | $-184,678,000 | $-181,119,000 |
| Net Income Continuous Operations | $-196,539,000 | $-260,602,000 | $-184,678,000 | $-181,119,000 |
| Pretax Income | $-196,042,000 | $-260,256,000 | $-184,114,000 | $-181,119,000 |
| Interest Income Non Operating | $15,293,000 | $14,711,000 | $13,945,000 | $4,029,000 |
| Operating Income | $-192,016,000 | $-265,503,000 | $-184,357,000 | $-179,157,000 |
| Gross Profit | $170,265,000 | $116,758,000 | $68,126,000 | $21,505,000 |
| Per Share | ||||
| Diluted EPS | $-3.11 | $-4.34 | $-3.20 | $-3.47 |
| Basic EPS | $-3.11 | $-4.34 | $-3.20 | $-3.47 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $1,869,000 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-174,121,000 | $-246,990,000 | $-168,464,000 | $-174,246,000 |
| Reconciled Depreciation | $1,338,000 | $1,563,000 | $1,758,000 | $1,672,000 |
| EBITDA (Bullshit earnings) | $-174,121,000 | $-238,090,000 | $-168,464,000 | $-174,246,000 |
| EBIT | $-175,459,000 | $-239,653,000 | $-170,222,000 | $-175,918,000 |
| Diluted Average Shares | $64,984,361 | $60,995,204 | $57,673,128 | $52,120,701 |
| Basic Average Shares | $64,984,361 | $60,995,204 | $57,673,128 | $52,120,701 |
| Diluted NI Availto Com Stockholders | $-201,917,000 | $-264,572,000 | $-184,678,000 | $-181,119,000 |
| Preferred Stock Dividends | $5,378,000 | $3,970,000 | - | - |
| Tax Provision | $497,000 | $346,000 | $564,000 | $0 |
| Research And Development | $167,340,000 | $237,957,000 | $134,951,000 | $108,630,000 |
| Selling General And Administration | $194,941,000 | $144,304,000 | $117,532,000 | $92,032,000 |
| Total Unusual Items | - | $8,900,000 | - | - |
| Total Unusual Items Excluding Goodwill | - | $8,900,000 | - | - |
| Gain On Sale Of Security | - | $8,900,000 | - | - |
Fetched: 2026-06-19
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $264,707,000 | $158,375,000 | $162,731,000 | $256,379,000 |
| Total Assets | $480,196,000 | $392,273,000 | $332,745,000 | $382,481,000 |
| Total Non Current Assets | $13,280,000 | $18,073,000 | $24,477,000 | $28,245,000 |
| Other Non Current Assets | $3,808,000 | $7,790,000 | $15,327,000 | $16,983,000 |
| Goodwill And Other Intangible Assets | $5,319,000 | $6,174,000 | $7,028,000 | $7,883,000 |
| Current Assets | $466,916,000 | $374,200,000 | $308,268,000 | $354,236,000 |
| Other Current Assets | $9,967,000 | $8,802,000 | $6,672,000 | $7,415,000 |
| Prepaid Assets | $16,166,000 | $7,580,000 | $2,259,000 | $4,392,000 |
| Inventory | $25,753,000 | $18,741,000 | $8,624,000 | $2,917,000 |
| Receivables | $26,081,000 | $18,512,000 | $14,867,000 | $6,224,000 |
| Accounts Receivable | $26,081,000 | $18,512,000 | $14,867,000 | $6,224,000 |
| Cash Cash Equivalents And Short Term Investments | $388,949,000 | $320,565,000 | $275,846,000 | $333,288,000 |
| Cash And Cash Equivalents | $54,301,000 | $89,137,000 | $60,081,000 | $127,677,000 |
| Debt | ||||
| Total Debt | $3,992,000 | $3,938,000 | $1,260,000 | $1,944,000 |
| Long Term Debt And Capital Lease Obligation | $3,342,000 | $3,938,000 | $490,000 | $1,260,000 |
| Current Debt And Capital Lease Obligation | $650,000 | - | $770,000 | $684,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $210,170,000 | $227,724,000 | $162,986,000 | $118,219,000 |
| Total Non Current Liabilities Net Minority Interest | $104,228,000 | $112,207,000 | $107,783,000 | $78,410,000 |
| Derivative Product Liabilities | $0 | $0 | $1,150,000 | $1,340,000 |
| Non Current Deferred Liabilities | $100,886,000 | $108,269,000 | $106,143,000 | $75,810,000 |
| Current Liabilities | $105,942,000 | $115,517,000 | $55,203,000 | $39,809,000 |
| Other Current Liabilities | $4,077,000 | $42,054,000 | $5,410,000 | $2,419,000 |
| Current Deferred Liabilities | $7,490,000 | $2,827,000 | $1,286,000 | $1,434,000 |
| Payables And Accrued Expenses | $93,725,000 | $70,636,000 | $47,737,000 | $35,272,000 |
| Payables | $13,947,000 | $12,328,000 | $4,885,000 | $4,797,000 |
| Accounts Payable | $13,947,000 | $12,328,000 | $4,885,000 | $4,797,000 |
| Equity | ||||
| Common Stock Equity | $139,069,000 | $21,729,000 | $169,759,000 | $264,262,000 |
| Preferred Stock Equity | $130,957,000 | $142,820,000 | - | - |
| Total Equity Gross Minority Interest | $270,026,000 | $164,549,000 | $169,759,000 | $264,262,000 |
| Stockholders Equity | $270,026,000 | $164,549,000 | $169,759,000 | $264,262,000 |
| Gains Losses Not Affecting Retained Earnings | $-796,000 | $-39,000 | $134,000 | $-92,000 |
| Other Equity Adjustments | $-796,000 | $-39,000 | $134,000 | $-92,000 |
| Retained Earnings | $-1,351,877,000 | $-1,155,338,000 | $-894,736,000 | $-710,058,000 |
| Other | ||||
| Ordinary Shares Number | $67,205,321 | $62,390,654 | $59,426,559 | $56,612,429 |
| Share Issued | $67,205,321 | $62,390,654 | $59,426,559 | $56,612,429 |
| Tangible Book Value | $133,750,000 | $15,555,000 | $162,731,000 | $256,379,000 |
| Invested Capital | $139,069,000 | $21,729,000 | $169,759,000 | $264,262,000 |
| Working Capital | $360,974,000 | $258,683,000 | $253,065,000 | $314,427,000 |
| Capital Lease Obligations | $3,992,000 | $3,938,000 | $1,260,000 | $1,944,000 |
| Total Capitalization | $270,026,000 | $164,549,000 | $169,759,000 | $264,262,000 |
| Additional Paid In Capital | $1,491,675,000 | $1,177,045,000 | $1,064,302,000 | $974,356,000 |
| Capital Stock | $131,024,000 | $142,881,000 | $59,000 | $56,000 |
| Common Stock | $67,000 | $61,000 | $59,000 | $56,000 |
| Preferred Stock | $130,957,000 | $142,820,000 | $0 | $0 |
| Long Term Capital Lease Obligation | $3,342,000 | $3,938,000 | $490,000 | $1,260,000 |
| Current Deferred Revenue | $194,000 | $1,286,000 | $1,286,000 | $1,434,000 |
| Current Capital Lease Obligation | $650,000 | $0 | $770,000 | $684,000 |
| Current Accrued Expenses | $79,778,000 | $58,308,000 | $42,852,000 | $30,475,000 |
| Net PPE | $4,153,000 | $4,109,000 | $2,122,000 | $3,379,000 |
| Accumulated Depreciation | $-5,249,000 | $-4,767,000 | $-4,059,000 | $-3,155,000 |
| Gross PPE | $9,402,000 | $8,876,000 | $6,181,000 | $6,534,000 |
| Leases | $2,733,000 | $2,705,000 | $2,705,000 | $2,705,000 |
| Construction In Progress | $926,000 | $0 | - | - |
| Other Properties | $3,049,000 | $3,477,000 | $781,000 | $1,182,000 |
| Machinery Furniture Equipment | $2,694,000 | $2,694,000 | $2,695,000 | $2,647,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $17,377,000 | $10,715,000 | $2,895,000 | $195,000 |
| Work In Process | $1,631,000 | $1,250,000 | $1,104,000 | $0 |
| Raw Materials | $6,745,000 | $6,776,000 | $4,625,000 | $2,722,000 |
| Other Short Term Investments | $334,648,000 | $231,428,000 | $215,765,000 | $205,611,000 |
Fetched: 2026-06-19
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-116,628,000 | $-113,879,000 | $-136,204,000 | $-177,709,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-115,675,000 | $-113,879,000 | $-136,157,000 | $-173,428,000 |
| Cash Flow From Continuing Operating Activities | $-115,675,000 | $-113,879,000 | $-136,157,000 | $-173,428,000 |
| Operating Gains Losses | $-910,000 | $-10,320,000 | $-190,000 | $790,000 |
| Investing Activities | ||||
| Capital Expenditure | $-953,000 | - | $-47,000 | $-4,281,000 |
| Investing Cash Flow | $-137,153,000 | $-48,173,000 | $-5,665,000 | $28,029,000 |
| Cash Flow From Continuing Investing Activities | $-137,153,000 | $-48,173,000 | $-5,665,000 | $28,029,000 |
| Net Other Investing Changes | $-40,000,000 | $-40,500,000 | $-5,667,000 | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $222,692,000 | $177,996,000 | $48,875,000 | $131,112,000 |
| Financing Cash Flow | $217,963,000 | $191,242,000 | $74,368,000 | $213,828,000 |
| Cash Flow From Continuing Financing Activities | $217,963,000 | $191,242,000 | $74,368,000 | $213,828,000 |
| Net Other Financing Charges | $-19,917,000 | $-4,000,000 | $16,972,000 | $72,338,000 |
| Net Preferred Stock Issuance | $0 | $138,850,000 | $0 | $0 |
| Preferred Stock Issuance | $0 | $138,850,000 | $0 | $0 |
| Net Common Stock Issuance | $222,692,000 | $39,146,000 | $48,875,000 | $131,112,000 |
| Common Stock Issuance | $222,692,000 | $39,146,000 | $48,875,000 | $131,112,000 |
| Other | ||||
| End Cash Position | $54,823,000 | $89,601,000 | $60,409,000 | $128,005,000 |
| Beginning Cash Position | $89,601,000 | $60,409,000 | $128,005,000 | $59,576,000 |
| Effect Of Exchange Rate Changes | $87,000 | $2,000 | $-142,000 | $0 |
| Changes In Cash | $-34,865,000 | $29,190,000 | $-67,454,000 | $68,429,000 |
| Proceeds From Stock Option Exercised | $15,188,000 | $17,246,000 | $8,521,000 | $10,378,000 |
| Net Investment Purchase And Sale | $-96,200,000 | $-7,673,000 | $49,000 | $32,310,000 |
| Sale Of Investment | $252,469,000 | $260,640,000 | $354,967,000 | $284,247,000 |
| Purchase Of Investment | $-348,669,000 | $-268,313,000 | $-354,918,000 | $-251,937,000 |
| Net PPE Purchase And Sale | $-953,000 | $0 | $-47,000 | $-281,000 |
| Purchase Of PPE | $-953,000 | $0 | $-47,000 | $-281,000 |
| Change In Working Capital | $-968,000 | $10,575,000 | $4,807,000 | $-17,410,000 |
| Change In Other Working Capital | $-1,092,000 | - | $-148,000 | $-6,606,000 |
| Change In Other Current Assets | $-397,000 | $7,943,000 | $1,656,000 | $-4,840,000 |
| Change In Payables And Accrued Expense | $21,892,000 | $21,918,000 | $14,773,000 | $1,543,000 |
| Change In Payable | $21,892,000 | $21,918,000 | $14,773,000 | $1,543,000 |
| Change In Account Payable | $21,892,000 | $21,918,000 | $14,773,000 | $1,543,000 |
| Change In Prepaid Assets | $-6,327,000 | $-5,524,000 | $2,876,000 | $498,000 |
| Change In Inventory | $-7,474,000 | $-10,117,000 | $-5,707,000 | $-2,806,000 |
| Change In Receivables | $-7,570,000 | $-3,645,000 | $-8,643,000 | $-5,199,000 |
| Changes In Account Receivables | $-7,570,000 | $-3,645,000 | $-8,643,000 | $-5,199,000 |
| Other Non Cash Items | $21,102,000 | $113,388,000 | $19,428,000 | $5,122,000 |
| Stock Based Compensation | $66,818,000 | $39,682,000 | $32,553,000 | $19,831,000 |
| Amortization Of Securities | $-6,516,000 | $-8,165,000 | $-9,835,000 | $-2,314,000 |
| Depreciation Amortization Depletion | $1,338,000 | $1,563,000 | $1,758,000 | $1,672,000 |
| Depreciation And Amortization | $1,338,000 | $1,563,000 | $1,758,000 | $1,672,000 |
| Gain Loss On Investment Securities | $-910,000 | $-10,320,000 | $-190,000 | $790,000 |
| Net Income From Continuing Operations | $-196,539,000 | $-260,602,000 | $-184,678,000 | $-181,119,000 |
| Net Intangibles Purchase And Sale | - | $0 | $0 | $-4,000,000 |
| Purchase Of Intangibles | - | $0 | $0 | $-4,000,000 |
| Net Business Purchase And Sale | - | - | $0 | $0 |
| Sale Of Business | - | - | $0 | $0 |
| Sale Of Intangibles | - | - | $0 | $0 |
| Gain Loss On Sale Of Business | - | - | $0 | $0 |
Fetched: 2026-06-19